Tuberculosis Treatment and Risk of Stavudine Substitution in First‐Line Antiretroviral Therapy | Zendy

Daniel Westreich | Zendy; Ian Sanne | Zendy; Mhairi Maskew | Zendy; Babatyi MalopeKgokong | Zendy; Francesca Conradie | Zendy; Pappie Majuba | Zendy; Michele Jönsson Funk | Zendy; Jay S. Kaufman | Zendy; Annelies Van Rie | Zendy; Patrick MacPhail | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tuberculosis Treatment and Risk of Stavudine Substitution in First‐Line Antiretroviral Therapy

Author(s) -

Daniel Westreich,

Ian Sanne,

Mhairi Maskew,

Babatyi MalopeKgokong,

Francesca Conradie,

Pappie Majuba,

Michele Jönsson Funk,

Jay S. Kaufman,

Annelies Van Rie,

Patrick MacPhail

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/598977

Subject(s) - medicine , stavudine , tuberculosis , antiretroviral therapy , human immunodeficiency virus (hiv) , virology , viral load , pathology

Treatment for tuberculosis (TB) is common among individuals receiving stavudine-containing highly active antiretroviral therapy (HAART), but the effect of TB treatment on stavudine toxicity has received little attention. We estimated the effect of TB treatment on risk of stavudine substitution among individuals receiving first-line HAART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research